Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective increased by JMP Securities from $114.00 to $125.00 in a report issued on Friday morning, Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock. BPMC has been the subject of a number of other research reports. Barclays lifted their target […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target boosted by equities research analysts at Barclays from $70.00 to $75.00 in a report released on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would suggest a potential downside of 30.23% from the […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective lifted by investment analysts at Barclays from $70.00 to $75.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would indicate a potential downside […]
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective lifted by investment analysts at Barclays from $70.00 to $75.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would indicate a potential downside […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $107.56 and last traded at $107.00, with a volume of 391291 shares. The stock had previously closed at $94.86. Wall Street Analyst Weigh In A number of brokerages […]